Found: 13
Select item for more details and to access through your institution.
Host cell proteins in biotechnology-derived products: A risk assessment framework.
- Published in:
- Biotechnology & Bioengineering, 2015, v. 112, n. 11, p. 2284, doi. 10.1002/bit.25647
- By:
- Publication type:
- Article
Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.
- Published in:
- AAPS Journal, 2017, v. 19, n. 6, p. 1656, doi. 10.1208/s12248-017-0128-y
- By:
- Publication type:
- Article
New FDA Draft Guidance on Immunogenicity.
- Published in:
- AAPS Journal, 2014, v. 16, n. 3, p. 499, doi. 10.1208/s12248-014-9587-6
- By:
- Publication type:
- Article
Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 6, p. 1393, doi. 10.1111/cts.13264
- By:
- Publication type:
- Article
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 141, doi. 10.1111/cts.13149
- By:
- Publication type:
- Article
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 130, doi. 10.1111/cts.13127
- By:
- Publication type:
- Article
Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates.
- Published in:
- AAPS Journal, 2024, v. 26, n. 4, p. 1, doi. 10.1208/s12248-024-00954-2
- By:
- Publication type:
- Article
Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy.
- Published in:
- Cancer Reports, 2022, v. 5, n. 10, p. 1, doi. 10.1002/cnr2.1578
- By:
- Publication type:
- Article
Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities.
- Published in:
- Antibodies (2073-4468), 2020, v. 9, n. 2, p. 7, doi. 10.3390/antib9020007
- By:
- Publication type:
- Article
Structural Analysis of the Human and Rat Androgen Receptors and Expression in Male Reproductive Tract Tissues.
- Published in:
- Annals of the New York Academy of Sciences, 1989, v. 564, n. 1, p. 48, doi. 10.1111/j.1749-6632.1989.tb25887.x
- By:
- Publication type:
- Article
Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 2, p. 211, doi. 10.1007/s00280-021-04276-4
- By:
- Publication type:
- Article
The quintessence of immunogenicity reporting for biotherapeutics.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 4, p. 334, doi. 10.1038/nbt.3181
- By:
- Publication type:
- Article
Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 988, doi. 10.1002/cpt.1694
- By:
- Publication type:
- Article